NDAORALSOLUTION
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYCOFENIX is a fixed-dose oral solution combining guaifenesin (expectorant), hydrocodone bitartrate (opioid cough suppressant), and pseudoephedrine hydrochloride (decongestant) approved in 2015. It is indicated for symptomatic relief of cough and congestion associated with upper respiratory tract conditions. The combination addresses multiple symptom pathways in a single formulation.
Peak
Product is in peak revenue stage with moderate competitive pressure (30%), indicating stable commercial operations but limited growth headroom; team size likely plateaued.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYCOFENIX offers stable, commercially-focused experience in a mature, multi-component cough-and-cold market. Career value lies in execution against competition, managed-care negotiations, and defending market share rather than product innovation or launch activities.
Brand ManagerField Sales Representative
Worked on HYCOFENIX at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.